TrialGynecologic oncology2023

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.

Maria M Rubinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.